Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703477 | 0.78 | DPP4 (0.60) | DPP4DPP8 | |
| SCHEMBL4705887 | 0.78 | DPP4 (0.60) | DPP4DPP8 | |
| SCHEMBL646823 | 0.78 | DPP4 (0.60) | DPP4DPP8 | |
| SCHEMBL14263071 | 0.78 | DPP4 (0.64) | DPP4DPP8 | |
| SCHEMBL4983693 | 0.78 | DPP4 (0.60) | DPP4DPP8 | |
| SCHEMBL4703476 | 0.78 | DPP4 (0.60) | DPP4DPP8 | |
| SCHEMBL25320589 | 0.76 | DPP4 (0.40) | DPP4DPP8 | |
| SCHEMBL25202753 | 0.76 | DPP4 (0.40) | DPP4DPP8 | |
| SCHEMBL25305608 | 0.76 | DPP4 (0.37) | DPP4DPP8 | |
| SCHEMBL25319437 | 0.76 | DPP4 (0.40) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152600-A1 | SYNTHESIS OF (2S,5R)-5-ETHYNYL-1-PYRROLIDINE-2-CARBONITRILE | ABBVIE INC (US) | 2016-06-02 | — | — | US | disclosed |
| US-9260411-B2 | Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile | ABBVIE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2535338-A1 | Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile | Abbott Laboratories (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2057145-B1 | SYNTHESIS OF (2S,5R)-5-ETHYNYL-1-{N-(4-METHYL-1-(4-CARBOXY-PYRIDIN-2-YL)PIPERIDIN-4-YL)GLYCYL}PYRROLIDINE-2-CARBONITRILE | ABBOTT LAB (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20080058528-A1 | useful in the treatment of disorders mediated by DPP-IV such as, but not limited to, diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152600-A1 | SYNTHESIS OF (2S,5R)-5-ETHYNYL-1-PYRROLIDINE-2-CARBONITRILE | PNN, PARN, AZI2 | DPP4 1253/4885DPP8 2673/4885 |
| US-20080058528-A1 | useful in the treatment of disorders mediated by DPP-IV such as, but not limited to, diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.